(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.52%) $79.67
(0.56%) $2.31
(0.55%) $2 353.10
(0.74%) $28.58
(0.19%) $992.70
(-0.32%) $0.927
(-0.39%) $10.85
(-0.24%) $0.798
(0.87%) $92.54
5.48% $ 3.27
@ $3.74
Emitido: 14 feb 2024 @ 12:33
Retorno: -12.57%
Señal anterior: feb 14 - 11:06
Señal anterior:
Retorno: 0.00 %
Live Chart Being Loaded With Signals
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...
Stats | |
---|---|
Volumen de hoy | 499 463 |
Volumen promedio | 1.18M |
Capitalización de mercado | 457.99M |
EPS | $0 ( 2024-03-26 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.35 |
ATR14 | $0.00500 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-08 | Ekblom Anders | Buy | 45 000 | Share Options (Right to buy) |
2024-02-08 | Ekblom Anders | Buy | 19 471 | Deferred Restricted Stock Units |
2024-02-08 | Jacquet Pierre | Buy | 45 000 | Share Options (Right to buy) |
2024-02-08 | Jacquet Pierre | Buy | 15 553 | Deferred Restricted Stock Units |
2024-02-08 | Yoskowitz Marc J | Buy | 45 000 | Share Options (Right to buy) |
INSIDER POWER |
---|
-60.62 |
Last 97 transactions |
Buy: 2 158 393 | Sell: 9 188 547 |
Volumen Correlación
Mereo BioPharma Group plc Correlación
10 Correlaciones Más Positivas | |
---|---|
CFBK | 0.888 |
SLNO | 0.887 |
PBPB | 0.885 |
PROV | 0.873 |
ECOR | 0.867 |
ARDX | 0.865 |
RBKB | 0.861 |
ISTR | 0.854 |
CXDO | 0.854 |
CPLP | 0.851 |
10 Correlaciones Más Negativas | |
---|---|
OSMT | -0.878 |
PFBI | -0.858 |
HCM | -0.847 |
MLVF | -0.847 |
IQ | -0.844 |
RMRM | -0.843 |
BFRI | -0.838 |
COCO | -0.833 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Mereo BioPharma Group plc Correlación - Moneda/Commodity
Mereo BioPharma Group plc Finanzas
Annual | 2023 |
Ingresos: | $10.00M |
Beneficio Bruto: | $7.43M (74.26 %) |
EPS: | $0 |
FY | 2023 |
Ingresos: | $10.00M |
Beneficio Bruto: | $7.43M (74.26 %) |
EPS: | $0 |
FY | 2022 |
Ingresos: | $1.51M |
Beneficio Bruto: | $571 000 (37.89 %) |
EPS: | $-0.280 |
FY | 2021 |
Ingresos: | $36.46M |
Beneficio Bruto: | $18.56M (50.89 %) |
EPS: | $0.159 |
Financial Reports:
No articles found.
Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico